search
Back to results

Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method

Primary Purpose

Allergic Reaction

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Test Article
Positive Control
Negative Control
Sponsored by
Omeza, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Allergic Reaction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy volunteers aged 18 years of age and older as demonstrated by selfreported medical history, concurrent medication, and a brief dermal skin assessment of the test sites;
  2. Fully informed of the risks of entering the study and willing to provide written informed consent and HIPAA authorization to disclose protected health information;
  3. Subject has normal healthy skin on the either volar forearm.

Exclusion Criteria:

Subjects must be excluded if any of the following conditions exist:

  1. Self-reported pregnant or nursing at the screening visit;
  2. Clinically significant skin disease which may contraindicate participation, including psoriasis, eczema, atopic dermatitis, and active cancer;
  3. History of drug abuse or current drug user;
  4. Treatment with antihistamine or steroid (any route) administered within the last 7 days;
  5. History of anaphylaxis to matrix ingredients (e.g. fish, palm oil, hemp oil, beeswax);
  6. Persistent severe/ unstable asthma;
  7. Subjects on beta blockers and/or ACE inhibitors;
  8. Medical condition which in the opinion of the Investigator would compromise the safety of the subject or confound study results (Subjects with the following conditions: chronic renal failure, CVA, cancer, spinal cord injury, diabetic neuropathy, recent anaphylaxis, limbs affected by lymphoedema, paralysis, or neurogenic abnormalities;
  9. Diabetic (type 1 or 2);
  10. Subjects taking the following: Antidepressants such as doxepin, other tricyclics, Phenothiazines, and tetracyclics within the last two weeks;
  11. Subjects taking OTC cold and flu remedies, "sinus" analgesics, antitussives, antiemetics, sedatives, relaxants, migraine prophylactics (cyproheptadine, pizotifen);
  12. Prolonged use of topical corticosteroids;
  13. Use of topical moisturizers on the volar forearms;
  14. Dermographism "writing on the skin" - common localized hive reaction, characterized by the abrupt onset of welts and hives where the skin is exposed to pressure, scratching, itching, or stroking;
  15. Investigator deems the subject an unsuitable candidate for this study.

Sites / Locations

  • PCR Corp

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

Test article

Histamine Positive Skin Test Control

Aqueous Negative Control

Arm Description

Outcomes

Primary Outcome Measures

Allergic Reaction
Response of at least 3-mm diameter (with equivalent erythema) more than negative control is required as proof of presence of cutaneous allergen specific IgE

Secondary Outcome Measures

Allergic Reaction
Latent reaction to skin prick (safety assessment)

Full Information

First Posted
August 10, 2020
Last Updated
August 10, 2020
Sponsor
Omeza, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04510376
Brief Title
Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method
Official Title
A Safety Study to Assess the Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
November 14, 2019 (Actual)
Primary Completion Date
November 14, 2019 (Actual)
Study Completion Date
November 14, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Omeza, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Single-center, monadic, one day study utilizing the skin prick method to assess the allergy potential of Omeza Collagen Matrix in Human Subjects

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Allergic Reaction

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Test article
Arm Type
Experimental
Arm Title
Histamine Positive Skin Test Control
Arm Type
Active Comparator
Arm Title
Aqueous Negative Control
Arm Type
Placebo Comparator
Intervention Type
Device
Intervention Name(s)
Test Article
Intervention Description
Omeza Collagen Matrix
Intervention Type
Other
Intervention Name(s)
Positive Control
Intervention Description
1.0 mg/mL Histamine Base
Intervention Type
Other
Intervention Name(s)
Negative Control
Intervention Description
Aqueous Negative Control
Primary Outcome Measure Information:
Title
Allergic Reaction
Description
Response of at least 3-mm diameter (with equivalent erythema) more than negative control is required as proof of presence of cutaneous allergen specific IgE
Time Frame
20 minutes
Secondary Outcome Measure Information:
Title
Allergic Reaction
Description
Latent reaction to skin prick (safety assessment)
Time Frame
60 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy volunteers aged 18 years of age and older as demonstrated by selfreported medical history, concurrent medication, and a brief dermal skin assessment of the test sites; Fully informed of the risks of entering the study and willing to provide written informed consent and HIPAA authorization to disclose protected health information; Subject has normal healthy skin on the either volar forearm. Exclusion Criteria: Subjects must be excluded if any of the following conditions exist: Self-reported pregnant or nursing at the screening visit; Clinically significant skin disease which may contraindicate participation, including psoriasis, eczema, atopic dermatitis, and active cancer; History of drug abuse or current drug user; Treatment with antihistamine or steroid (any route) administered within the last 7 days; History of anaphylaxis to matrix ingredients (e.g. fish, palm oil, hemp oil, beeswax); Persistent severe/ unstable asthma; Subjects on beta blockers and/or ACE inhibitors; Medical condition which in the opinion of the Investigator would compromise the safety of the subject or confound study results (Subjects with the following conditions: chronic renal failure, CVA, cancer, spinal cord injury, diabetic neuropathy, recent anaphylaxis, limbs affected by lymphoedema, paralysis, or neurogenic abnormalities; Diabetic (type 1 or 2); Subjects taking the following: Antidepressants such as doxepin, other tricyclics, Phenothiazines, and tetracyclics within the last two weeks; Subjects taking OTC cold and flu remedies, "sinus" analgesics, antitussives, antiemetics, sedatives, relaxants, migraine prophylactics (cyproheptadine, pizotifen); Prolonged use of topical corticosteroids; Use of topical moisturizers on the volar forearms; Dermographism "writing on the skin" - common localized hive reaction, characterized by the abrupt onset of welts and hives where the skin is exposed to pressure, scratching, itching, or stroking; Investigator deems the subject an unsuitable candidate for this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lynne Ellis, M.D.
Organizational Affiliation
PCR Corp
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lori Decaro
Organizational Affiliation
PCR Corp
Official's Role
Study Director
Facility Information:
Facility Name
PCR Corp
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33702
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/allergydiagnostictesting.pdf
Description
Allergy Diagnostic Testing: An Updated Practice Parameter

Learn more about this trial

Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method

We'll reach out to this number within 24 hrs